Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Background: In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, atorvastatin was compared with placebo in 4,731 participants with recent stroke or transient ischemic attack and no known coronary heart disease. Atorvastatin reduced the first occurrence of stroke and the first occurrence of a composite of vascular events. Objectives: The aim of this post hoc analysis was to assess the occurrence of all (first and subsequent) vascular events and the effect of atorvastatin to reduce these events by vascular territory (cerebrovascular, coronary, or peripheral) in SPARCL. Methods: Treatment effects on total adjudicated vascular events, overall and by vascular territory, were summarized by marginal proportional hazards models. Vascular event rates were estimated for each treatment group with cumulative incidence functions. Results: The placebo group had an estimated 41.2 first and 62.7 total vascular events per 100 participants over 6 years. There were 164 fewer first and 390 fewer total vascular events in the atorvastatin group (total events hazard ratio: 0.68; 95% confidence interval: 0.60 to 0.77). The total events reduction included 177 fewer cerebrovascular, 170 fewer coronary, and 43 fewer peripheral events. Over 6 years, an estimated 20 vascular events per 100 participants were avoided with atorvastatin treatment. Conclusions: In participants with recent stroke or transient ischemic attack, the total number of vascular events prevented with atorvastatin was more than twice the number of first events prevented. Total event reduction provides a comprehensive metric to capture the totality of atorvastatin clinical efficacy in reducing disease burden after stroke or transient ischemic attack.

Original languageEnglish
Pages (from-to)2110-2118
Number of pages9
JournalJournal of the American College of Cardiology
Issue number17
StatePublished - May 5 2020

Bibliographical note

Publisher Copyright:
© 2020 American College of Cardiology Foundation


  • atorvastatin
  • stroke
  • total events
  • transient ischemic attack

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial'. Together they form a unique fingerprint.

Cite this